Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions
| Autor: | Barry A. Borlaug, Christopher M. O'Connor, Bernard J. Gersh, Yogesh N.V. Reddy |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Heart Failure
medicine.medical_specialty Ejection fraction business.industry Chronic systolic heart failure Stroke Volume Atrial fibrillation 030204 cardiovascular system & hematology Prognosis medicine.disease Ventricular Dysfunction Left 03 medical and health sciences 0302 clinical medicine Heart failure Atrial Fibrillation medicine Humans 030212 general & internal medicine Cardiology and Cardiovascular Medicine Intensive care medicine business Percutaneous Mitral Valve Repair Heart Failure Systolic |
| Zdroj: | European Heart Journal. 41:1764-1774 |
| ISSN: | 1522-9645 0195-668X |
| DOI: | 10.1093/eurheartj/ehz364 |
| Popis: | Despite improvements in outcomes in the last few decades for heart failure (HF) with reduced ejection fraction (HFrEF), there still remains a need for novel therapies as many patients incompletely recover with existing therapies and progress to advanced HF. In this review, we will discuss recent advances in the management of HFrEF with a focus on upcoming therapies that hold the greatest promise for clinical use. We will discuss novel pharmacological therapies and areas of uncertainty with existing therapies. We will also discuss the potential utility and controversy surrounding novel interventions for HF such as percutaneous mitral valve repair, atrial fibrillation ablation, and other emerging interventions with positive signals for benefit in HFrEF. Finally, we will summarize the current state of stem cell and gene therapy for HFrEF and future directions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|